Optimum methods of harvesting circulating hematopoietic progenitors for autologous transplantation t o support myeloablative cancer therapy are still uncertain, mostly because of the lack of an assay for marrow-repopulating stem cells. The CFU-GM assay, the commonly used indirect indicator of the quality of the graft, is poorly standardized and provides results evaluable only retrospectively. Based on the knowledge that hematopoietic progenitors express CD34 and CD33 differentiation antigens, we developed a dual-color direct immunofluorescence flow cytometry assay with the aim of replacing the CFU-GM assay advantageously. For this purpose, we applied both assays t o 157 blood samples obtained daily throughout 20 different recoveries from pancytopenia induced by high-dose cyclophosphamide or etoposide cancer therapy with or without recombinant human GM colonystimulating factor (rhGM-CSF). The appearance of CD34' cells in the circulation indicated that hematopoietic progenitors had increased t o more than 500 CFU-GM/mL, a level
H ripheral blood (PB) can be harvested, cryopreserved, and then transplanted to reconstitute the hematopoietic system of cancer patients treated with potentially curative, although myeloblative, high doses of radiotherapy, chemotherapy, or both.',* In recent years, autologous transplantation of circulating hematopoietic progenitor cells has attracted considerable clinical interest because of several potential advantages in comparison with bone marrow (BM)-derived hematopoietic progenitors. These advantages include the possibility of (a) circumventing the need of general anesthesia; (b) harvesting even if iliac bones are damaged by previous radiotherapy or infiltrated with malignant cells; and (c) most important, achieving restoration of sustained hematopoietic functions more rapidly than with BM-derived progenitor cells.'~2 The latter advantage, if confirmed as reproducible in controlled clinical studies with large series of patients, will probably represent considerable progress in improving the therapeutic index of high-x = 0 3 4 ' cells per microliter. Moreover, in a series of six patients treated with myeloablative chemoradiotherapy, early hematopoietic recovery of marrow functions was predicted more accurately by the number of transplanted CD34'/CD33' cells than by either total nucleated cells, CFU-GM, CD34+/ CD33-cells, or CD34-/CD33+ cells. Data presented in this article favor clinical use of the CD34/CD33 flow cytometry assay t o guide harvesting of circulating hematopoietic progenitors for autologous transplantation and contribute t o better understanding of the role played by circulating hematopoietic progenitor cell subsets in marrow recovery after myeloablative cancer therapy. 0 1991 by The American Society of Hematology.
dose radiotherapy, chemotherapy, or both for selected malignancies.
The quantity and quality of circulating hematopoietic progenitor cells required for successful (ie, rapid, complete, and sustained) hematopoietic reconstitution after myeloablative cancer therapy is still uncertain. Because the marrowrepopulating pluripotent stem cell cannot be identified in humans, the committed progenitor CFU-GM is the most commonly considered indirect indicator of marrow-repopulating ability. The threshold dose of circulating CFU-GM for successful transplantation varies widely in different reports, ranging between 15 and 50 x lo4 CFU-GM per kilogram of patient body weight.13*Such large quantities of progenitors can be harvested from PB by a practical number of leukaphereses in a reasonable time, ie, two to five daily leukaphereses in 2 to 5 consecutive days, only at the time of marrow recovery from cancer chemotherapyinduced pancytopenia. This timing is motivated by the occurrence of an outburst of hematopoietic progenitor cells in the circulation, especially when intensive chemotherapy is followed by administration of recombinant human GM colony-stimulating factor (rhGM-CSF).334 It is unfortunate that the outburst does not occur invariably in all patients, and its magnitude may vary in each individual case depending on a variety of partly explained factors? Presently, the CFU-GM colony assay provides some quantitative information on the hematopoietic progenitor cells contained in a given blood sample. This assay is poorly standardized among different laboratories because of its complex nature, involving fastidious pretesting of materials just to maintain reproducibility in each laboratory. Consequently, circulating CFU-GM are not strictly comparable among different institutions and problems inherent in the technique itself partly account for the wide ranges of the CFU-GM threshold doses reported in the literature.'.' Furthermore, the 2-week wait necessary before results are available also disqualifies the CFU-GM assay from being used clinically
as a real-time guide to harvest recovery-phase blood cells when an outburst of circulating hematopoietic progenitor cells is expected to occur.
Circulating hematopoietic progenitor cells can be distinguished by flow cytometry based on expression of surface membrane molecules referred to as CD34 and CD33 antigens similar to their BM counterpart4 Cells expressing the CD34 antigen (CD34+ cells) comprise virtually all hematopoietic progenitors forming CFU-GM, BFU-E, megakaryocytic (CFU-Mk), multilineage (CFU-Mix), and blast cell colonies (CFU-Blast): The latter undifferentiated hematopoietic progenitors notably possess many of the features of stem cells in that they are capable of selfrenewal and also of commitment to a number of hematopoietic lineages. In accordance with this in vitro finding, transplantation of enriched populations of autologous CD34' cells completely restores hematopoiesis of lethally irradiated baboons' and probably of patients treated with myeloablative cancer therapy.* Furthermore, CD34' cells can be divided into functionally distinct progenitor populations based on their expression of the CD33 antigen. The earliest progenitors, such as CFU-Blast and long-term culture initiating cells, express the CD34 antigen exclusively (CD34'/CD33-), whereas more differentiated committed colony-forming progenitors express both the CD34 and CD33 antigens (CD34+/CD33+).4s9 Based on this knowledge, we evaluated the clinical feasibility of using a flow cytometry assay instead of a colony assay to estimate hematopoietic progenitor cells circulating in the PB of cancer patients recovering from pancytopenia induced by intensive chemotherapy with or without rhGM-CSF.
Our first aim was to develop a simple and reproducible assay to be used clinically to decide on a real-time basis (a) which patients experience an overshoot of circulating hematopoietic progenitors of relevant magnitude for considering the large-scale collection of these cells by leukapheresis(es), (b) when leukaphereses should be performed, and (c) how many consecutive leukapheresis procedures are necessary to harvest quantities of hematopoietic progenitor cells sufficient for successful transplantation. Our second aim was to determine whether information on hematopoietic progenitor cell subsets provided by the CD34 and CD33 immunofluorescence analysis will predict the marrowrepopulating ability of transplanted PB autologous grafts.
MATERIALS AND METHODS
In a series of 16 patients, 20 high-dose chemotherapy courses and relative hematopoietic recoveries were evaluated (Table 1) . In all patients, BM status was assessed by morphological analysis of bilateral (Hodgkin's disease and non-Hodglun's lymphoma) or monolateral iliac crest marrow aspirates and biopsies. After patients had given written informed consent, they were treated according to high-dose sequential chemotherapy protocols approved by the institute's committee for clinical investigation. Table 1 .
During hematopoietic recovery after transient pancytopenia induced by HD-CTX or HD-VP16, PB buQ-coat cells were collected and cryopreserved to be used as the source of hematopoietic stem cells to support subsequent myeloablative cancer treatments (ie, 10 to 12.5 Gy total body irradiation and 120 to 140 mg/m' melphalan for Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma or 200 mg/m2 melphalan for breast cancer). After therapy with HD-CTX or HD-VP16 with or without rhGM-CSF and starting on the first day leukocyte counts reached 2 1,000/pL and platelet counts reached t 70,000/pL, patients underwent PB leukaphereses on 3 to 4 consecutive working days with a continuous-flow blood cell separator (IBM-COBE 2997, MEDAS, Genoa, Italy), according to a previously described technique.12 Total blood volume processed in each leukapheresis was between 7 and 10 L at a flow rate of 30 to 45 mWmin, which resulted in harvested cell suspensions of 250 to 300 mL.
Evaluation of circulating hematopoietic progenitors by flow cytomefry and colony assay. Circulating hematopoietic progenitors were identified blindly in the same samples by independent operators as cells expressing the surface membrane CD34 and/or CD33 antigen(s) by flow cytometry as well as cells forming CFU-GM by colony assay under appropriate culture conditions in semisolid medium.
Cells expressing the surface membrane CD34 and/or CD33 antigen(s) were identified by flow cytometry using indirect CD34/ direct CD33 immunofluorescence in preliminary comparative experiments and by direct CD34/CD33 immunofluorescence in all subsequent analyses. For indirect immunofluorescence, the CD34 anti-HPCA-1 (MylO) monoclonal antibody (MoAb)" (Becton Dickinson, Mountain View, CA), and FITC-conjugated F(ab')2 goat anti-mouse Ig reagent (Technogenetics, Trezzano Naviglio, Italy) were used as previously described: For dual-color direct immunofluorescence analysis by flow cytometry, a small aliquot (50 pL) of heparinized whole PB or leukapheresis cell suspension was incubated with a mixture of CD34 FITC-conjugated 8G12 antibody (2 pL 0.25 mg/mL reagent)14a15 and CD33 phycoerythrin (PE)-conjugated Leu M9 antibody16 (15 pL) (Becton Dickinson) for 25 minutes at 4°C. In the case of leukocytes < 150/pL, the quantity of blood and antibodies was doubled. After incubation, erythrocytes were lysed with NH4Cl buffer (NH,Cl 8.29 g/L, KHCO, 1 g/L, 4 X NaEDTA 0.037 g/L, pH 7.4) for 10 minutes at room temperature, washed twice with 0.1% sodium azide in phosphate-buffered saline (PBS), and then analyzed by flow cytometry using a FAC-STAR cell sorter (Becton Dickinson) equipped with argon-ion laser tuned at 488 nm, power emission of 150 mW, and filter set for FITC-PE dual-color fluorescence. The entire nucleated cell population (ie, comprising mononuclear and polymorphonuclear cells) was taken into account; the acquisition gate excluded only occasional cell aggregates and debris. Ten thousand cells were acquired in list mode, and the frequency of the cells expressing CD34 and/or CD33 antigen(s) was calculated as percentage of all analyzed cells. This procedure was established to allow comparison of the hematopoietic cell frequencies estimated by flow cytometry with those obtained by CFU-GM colony assay (described below) without bias owing to cell separation maneuvers and electronic gating of the different cell subsets. Antigen(s)-positive cells were defined in contour diagrams taking into account the antibody-negative cell cluster without subtracting background fluorescence, according to the method previously described in detail." Cell frequencies of less than 0.5% positive cells were computed as zero cells unless a clear-cut positive cluster was evident by bivariate fluorescenceright angle cytometry analysis. Because both immature myeloid and mature polymorphonuclear cells dimly stained with PEconjugated CD33 antibody, we operationally defined as CD34-/ CD33+ cells only those with bright fluorescence and cytometric features of mononuclear cells. The count of circulating CD34'/ CD33-, CD34+/CD33', and CD34-/CD33+ cells was determined by multiplying their frequency (number of positive cells/number of analyzed leukocytes) by the leukocyte count in the same blood or leukapheresis sample. Cell counts and differentials were performed by H6000 automated hemocytometer (Technicon, Rome, Italy). In untreated patients with solid tumors in the steady state, CD34+ cells are not detectable in PB. 4 The intrinsic accuracy of flow cytometry, as measured by calculation of the coefficient of variation (CY) of 100 triplicate samples, was 1% to 6%.
The possibility that nonspecific binding of the FITC-conjugated 8G12 antibody to recovely-phase hematopoietic cells could also account for CD34+ cell counts was ruled out using a PEconjugated isotype-matched (IgG1) irrelevant CD19 antibody control as described previously! For CFU-GM colony assay, 5 mL heparinized whole blood was erythrocyte-depleted by gravity sedimentation with 33% Emagel (Behring, Scoppito, Italy) for 30 minutes at 37°C; the leukocyteenriched fraction was then cultured in triplicate at 20,000 to 400,000 cells/mL in semisolid medium, as described elsewhere.'* Leukapheresis cell suspensions were cultured at the same cell concentration without erythrocyte depletion because their hematocrit was less than 3% in all cases.12 CFU-GM were assayed in Iscove's modified Dulbecco's medium (IMDM, GIBCO, Paisley, England) containing 0.3% agar, 20% fetal calf serum (Flow, Opera, Italy), and 10% a 6 3 7 bladder carcinoma cell line conditioned medium as source of CSFs. After 7 and 14 days of incubation at 37°C in 5% C02/95% humidified air atmosphere, CFU-GM ( t 50 cells per aggregate) were scored under an inverted microscope. The count of circulating CFU-GM was determined by multiplying their frequency (number of colonies/number of cultured leukocytes) by the leukocyte count in the same sample.
In our laboratory, using the above technique and materials in untreated patients with solid tumors without BM involvement, the median value of steady-state circulating CFU-GM was 149 (range 39 to 329) colonies per milliliter of PB.5," The intrinsic accuracy of CFU-GM colony assay, as measured by calculation of the CV of 100 triplicate samples, was 1% to 30% when the plating efficiency corresponded to 50 to 150 colonies per culture dish and more than 30% with lower or higher colony numbers.
We estimated the relationship between counts of circulating hematopoietic progenitors evaluated by flow cytometry and colony assay by linear regression and correlation analysis using a commercially available computer program (Statworks, Cricket Software, Philadelphia, PA). We used the same program to calculate the CV of results of the two assays.
Statistical anabsis. tages: (a) considerably lower autofluorescence of the negative cell fraction (Fig 1) ; (b) the need for two (FITC-CD34 and PE-CD33 antibodies) instead of three (CD34 antibody, FITC-conjugated F(ab')* goat anti-mouse Ig antiserum, 
RESULTS

Comparison between indirect and direct immunofluores-
DAY +17
and PE-CD33) reagents, one of which is not monoclonal and thus is variable with each preparation; and (c) simpler and faster sample processing, implying 50 minutes instead of 150 minutes. Furthermore, using dual-color immunofluorescence as described in this article, CD34'/CD33-and CD34'/CD33' cell percentages were clearly ascertainable in blood samples despite wide variations of leukocyte counts ranging between 100 and 20,0OO/kL (Figs 2 through  4) . Based on these observations, all subsequent analyses of hematopoietic progenitors were performed with dual-color CD34 and CD33 direct immunofluorescence by flow cytometry in parallel to triplicate CFU-GM colony assay.
Circulation of hematopoietic progenitors was a transient and dynamic phenomenon. As shown in Figs 2 and 3 for the same representative patient, CD34'/CD33-and CD34+/ CD33' cells appeared in the circulation during hematopoietic recovery after chemotherapy-induced pancytopenia. Their number per microliter reached a peak during the third week after chemotherapy and then decreased to undetectable levels after 2 to 4 days in parallel with the increase of mononuclear CD34-/CD33' cells with bright fluorescence, the latter phenotype representing mostly immature, though nonclonogenic, granulomonocytic cells. Any combination of phenotypes, ie, CD34+/CD33-and CD34+/CD33 + (Fig 4, middle panel) , or CD34+/CD33- (Fig 4, left panel) , or CD34+/CD33+ (Fig 4, right panel) could be found without a clear pattern across the spectrum of patients studied.
Flow cytomety versus colony assay to estimate circulating hematopoietic progenitors. For the purpose of this study, we evaluated whole blood samples from patients expected to experience overshoot of circulating hematopoietic progenitors of variable magnitude depending on type of malignancy, presence or absence of BM involvement, chemotherapy, and rhGM-CSF administration? Counts of leukocytes, Because CFU-GM colony assay represents the currently used method of enumerating hematopoietic progenitors, we compared CFU-GM results with those of CD34 and CD33 dual-color immunofluorescence by flow cytometry as well as with leukocyte counts. The latter variable was taken into account to determine whether simple leukocyte counts during hematopoietic recovery after chemotherapy are themselves predictors of increasing numbers of hematopoiples are shown in Fig 2. etic progenitors. Day 7 and day 14 CFU-GM values were plotted against measurements of leukocytes, CD34'/ CD33-, CD34'/CD33', total CD34', and CD34-/CD33' cells. All variables tended to increase with increasing CFU-GM levels. The strength of these positive correlations was measured by calculating the correlation coefficient (r) ( Table 2 ). Leukocyte counts correlated poorly with CFU-GM (r = .56 and r = .67 with day 7 and day 14 CFU-GM, respectively) and total CD34' cells (r = .49), demonstrating that increasing leukocyte counts after chemotherapy do not necessarily reflect expansion of the compartment of circulating hematopoietic progenitors. As expected, virtually no correlation was found between .
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Results relative to analyses of 157 PB specimens were plotted on horizontal h) and vertical ( y ) axis. All variables tended to increase with increasing CFU-GM levels. The strength of these positive correlations was measured by calculating the correlation coefficient r as indicated.
circulating CFU-GM and the number of CD34-/CD33' cells (r = .ll and r = .18 with day 7 and day 14 CFU-GM, respectively). Determinations of CD34'/CD33-, and total CD34'/CD33', and total CD34' cells correlated well with those of CFU-GM. In particular, the best positive correlation was found between circulating day 14 CFU-GM and the total number of CD34' cells (r = .89). Data relative to day 14 CFU-GM and total CD34' cells ( matopoietic progenitors increased threefold above steadystate values, their increase was measurable indifferently either by CFU-GM colony assay or by CD34 direct immunofluorescence and flow cytometry.
Flow cytomeq v colony assay to determine peak counts of circulating hematopoietic progenitors after chemotherapy. Optimum harvesting of hematopoietic progenitor cells by leukaphereses requires the knowledge of their outburst timing in PB. Because of the 2-week wait necessary until colony results are available, the CFU-GM assay provides information usable only retrospectively. To determine if same-day determinations of circulating CD34' cell numbers by flow cytometry can be used to guide leukaphereses, we evaluated when hematopoietic progenitor cell peak counts were detected by using flow cytometry or CFU-GM colony assay. Table 4 shows that in our series of 20 hematopoietic recoveries after chemotherapy circulating hematopoietic progenitors were detected as CD34' cells or day 14 CFU-GM in 75% and 100% of patients, respectively. Patients 2, 3, 15, 16, and 19 had undetectable levels of circulating CD34' cells because the levels of hematopoietic progenitor cells as demonstrated by CFU-GM assay remained below the threshold of detection by flow cytometry. Among the remaining 15 evaluable patients, 11 (73%) were shown to have peak counts of hematopoietic progenitors on the same day by both methods; in the remaining four patients (27%), the peak of CD34' cells anticipated that of CFU-GM by 1 day.
Characterization of hematopoietic progenitor cells used for autologous transplantation after myeloablative therapy. Six consecutive patients were treated with total body irradiation plus melphalan and then transplanted with PB cells harvested at the time of hematopoietic recovery after HD-CTX or HD-VPl6. Transplanted hematopoietic progenitors were characterized in parallel by CFU-GM colony assay as well as by CD34 and CD33 flow cytometry (Table  5 ). In five of six patients, the dose of transplanted day 14 CFU-GM was 1.6-to 9.1-fold higher than the maximum proposed threshold dose of 50 x 104/kg.' According to the regression equation shown in Fig 5, the 50 x lo4 CFU-GM/kg threshold dose should correspond to 7.8 x lo6 total CD34' cells/kg. In practice, in the five patients transplanted with more than 50 x lo4 day 14 CFU-GM/kg, the dose of total CD34+ cells comprised between 21.8 x lo6 and 77.7 x 106/kg, (ie, 2.7-to 9.9-fold higher than the estimated total CD34' cell threshold dose). In patient 18, the dose of transplanted day 14 CFU-GM as well as total CD34' cells corresponded to approximately half of both threshold
For doses. Table 6 shows that patients who received more than 80 x lo4 day 14 CFU-GM per kilogram or more than 20 x 106 total CD34+ cells per kilogram experienced extraordinarily rapid and complete hematopoietic recovery. The only patient (patient 18) who received a lower dose of hematopoietic progenitors (23.3 x lo4 day 14 CFU-GM per kilogram or 4.65 X lo6 total CD34' cells per kilogram) experienced unsatisfactory platelet recovery and slower recovery of leukocytes and erythrocytes. Thus, these data further indicate that determinations of the number of total CD34' cells can be used to estimate the number of hematopoietic progenitors in autologous PB grafts. In this limited and heterogeneous series of patients (with or without BM involvement, with or without rhGM-CSF after transplantation, glycosylated or nonglycosylated rhGM-CSF), among the six parameters that we used to characterize the circulating progenitor cell graft (nucleated cells, +14  +14  +14  +19  +16  +15  +15  +15  +15  +16  +14  +17  +17  +12  +17  +16  +16  +22  +14 *Patient number refers to unique patient number shown in Table 1 . tNumber of days after chemotherapy when the peak count was detected.
CD34'/CD33-cells, CD34+/CD33+ cells, CD34-/CD33' cells, day 14 CFU-GM), the best predictor of the rate of early hematopoietic engraftment appeared to be the number of transplanted CD34+/CD33' cells (Table 6 ).
DISCUSSION
Cancer patients treated with intensive chemotherapy may or may not experience an expansion of the circulating hematopoietic progenitor cell compartment of sufficient magnitude to justify large-scale collection of these cells for subsequent autologous transplantation after further myeloablative cancer therapy.' Lack of a clinical assay for real-time determination of the number of circulating hematopoietic progenitors can expose patients with scarce or without overshoot of circulating hematopoietic progenitor cells to insufficient or useless leukapheresis procedures. To overcome this problem, we developed a dual-color CD34/ CD33 direct immunofluorescence assay suitable for clinical estimation of circulating hematopoietic progenitor cells. Recent availability of the 8G12 MoAb that, unlike all other CD34 antibodies to date, can be directly labeled with fluorochromes without loss of binding properties provided advantageous direct imm~nofluorescence.'~~'~ We report that a strong positive correlation exists between circulating CFU-GM colonies and either total CD34' cells, CD34'/CD33-cells, or CD34'/CD33' cells. This observation demonstrates that counts of CFU-GM, the committed progenitor so far used to judge the engraftment capability of autologous PB grafts, are good indirect indicators of the other nongranulomonocytic hematopoietic progenitors existing among CD34+ cells. Furthermore, because of the correlation existing between measurements of circulating CFU-GM and total CD34' cells, it is appropriate to use detection of total CD34' cells by flow cytometry assay to estimate the number hematopoietic progenitor cells that can be harvested clinically.
During steady-state hematopoiesis, total CD34' cells are undetectable in PB because levels of circulating hematopoietic progenitors are below the threshold of detection by flow cytometry. During recovery from pancytopenia induced by intensive HD-CTX or HD-VP16 cancer therapy with or without rhGM-CSF, the appearance of total CD34+ cells in the circulation indicates that hematopoietic progenitor cells have risen to levels corresponding to more than 500 CFU-GM per microliter, ie, at least threefold more Table 1 , and days of leukapheresis indicate number of days after chemotherapy when leukapheresis was performed.
than steady-state values. The highest and possibly safest threshold dose of autologous mobilized circulating hematopoietic progenitors to be transplanted for successful reconstitution of marrow functions in myeloablated patients is 50 x 1 0 4 CFU-GM per kilogram of body weight.'.' According to our regression equation describing the relationship between circulating CD34' cells and CFU-GM, this threshold dose corresponds to 7.8 x lo6 total CD34' cells per kilogram of body weight. Thus, during hematopoietic recovery after intensive chemotherapy-induced pancytopenia, the appearance of CD34' cells in the circulation indicates that a clinically relevant overshoot of hematopoietic progenitor cells is occurring. As a possible guideline, provided platelet counts are 2 70,OOO/pL, PB leukapheresis should be started as soon as CD34' cells appear in the circulation and continued until the threshold dose of 7.8 X lo6 CD34' cells per kilogram of body weight is achieved.
Recovery of marrow functions after myeloablative chemoradiotherapy and transplantation of autologous hematopoietic progenitor cells is a complex and partly understood phenomenon. Experimental studies in rodentdg and retrospective evaluation of available clinical data in humans' indicate that transplantation is followed by two phases of engraftment associated with hematopoietic progenitors at different stages of maturation. An initial phase corresponding to early hematopoietic recovery is produced by transFor personal use only. on October 23, 2017. by guest www.bloodjournal.org From progenitor cells is shown in Table 5 10. Gianni AM, Bregni M, Siena S, Orazi A, Stern AC, Gandola L, Bonadonna G: Recombinant human granulocyte macrophage colony stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkm's lymphoma. J Clin Oncol 8:768, 1990 11. Gianni AM, Tarella C, Siena S, Bregni M, Boccadoro M, Lombardi F, Bengala C, Bonadonna G, Pileri A. Durable and complete engraftment of rhGM-CSF exposed peripheral blood progenitor cells. Bone Marrow Transplant 6:143,1990 For personal use only. on October 23, 2017. by guest www.bloodjournal.org From
